Biologics remain one of the most active corners of spine and orthopedics, with new bone graft clearances, distribution deals and pipeline milestones landing across 2026.
Here are recent developments worth tracking.
- Medtronic won an expanded FDA approval for Infuse. On Feb. 13, the FDA granted premarket approval for Infuse bone graft in one- and two-level transforaminal lumbar interbody fusion procedures from L2-S1, with both Peek and titanium cages. Medtronic said the approval makes Infuse the only growth-factor bone graft approved for spine fusion including two-level TLIF constructs. The clearance followed a breakthrough device designation and a randomized study stopped early for success.
- OrthoPediatrics moved into metal-free pediatric fixation. In June, OrthoPediatrics signed an exclusive agreement to distribute OSSIO’s bio-integrative OSSIOfiber implants to U.S. children’s hospitals for pediatric fractures and deformities. The implants integrate into bone within 18 to 24 months, leaving no permanent hardware and aiming to reduce the removal surgeries common in pediatric metal fixation.
- Aurora Spine launched a dedicated biologics division. In October, Aurora Spine introduced Aurora Biologics, a spinal fusion portfolio made from 100% allograft bone that includes the Turbo Fuse fiber putty, Osteoporosis Graft DBM putty and Osteoporosis Bridge sponge strips.
- Kuros Biosciences launched a minimally invasive delivery system. On Sept. 30, Kuros released its MagnetOS minimally invasive spine delivery system in a full commercial launch. The bone graft delivery system is sterile, prefilled, free of human tissue and backed by what the company calls level I clinical evidence.
- Atreon Orthopedics and RenovoDerm merged. On May 19, the two companies combined to build a platform spanning synthetic biomaterials and unified Autobiologic technology. Atreon is known for its synthetic scaffolds for tendon-to-bone healing and RenovoDerm for its Phoenix wound matrix. The merged company will target durable tissue repair across a range of orthopedic applications.
- MTF Biologics and Kolosis BIO launched a new DBM fiber graft. On March 31, the partners introduced DBX Fiber, a fiber-tissue form processed for improved handling and osteoinductive potential. It expands the DBX portfolio, which also includes DBX Mix and DBX Putty, as Kolosis builds out its spine and orthopedics orthobiologics line.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
